AP-HP, Europe’s Leading Clinical Research Center, & IQVIA Collaborate to Launch the Largest Clinical Investigation Site in ...
January 23 2020 - 08:00AM
Business Wire
Assistance Publique – Hôpitaux de Paris (AP-HP), Europe's
leading clinical research center, joins IQVIA™, the global health
technology and human data science company, to launch the Paris
Prime Site for clinical trials. This AP-HP partnership represents
IQVIA’s second Prime Site within France, as well as the 43rd
globally, the 18th within Europe and largest research facility of
its kind within that region.
For IQVIA, the Prime Site designation assures its partner
pharmaceutical and biotech companies that their clinical trials
will take place in premier investigative research centers with
recognized professionals and with infrastructure focused on
innovation and research development for patients. IQVIA will
provide staff entirely dedicated to AP-HP, including a Prime Site
manager, who will oversee partnership relations and follow-up on
the delivery of IQVIA research projects. AP-HP and IQVIA will
collaborate on research programs to optimize processes, reduce the
time to start clinical research, align procedures and support a
significant increase in complex clinical trials and real-world
evidence studies within France and Europe.
Florence Favrel-Feuillade, director of the Delegation for
Clinical Research and Innovation, AP-HP, said, “The partnership
between AP-HP and IQVIA is a strong signal of AP-HP's willingness
to position itself as one of the world's leading reference centers
for clinical investigation, particularly to enable patients to
benefit from the most innovative treatments.”
Alistair Grenfell, president Europe, Middle East, and Africa,
IQVIA, said, “The opening of the Paris Prime Site marks a
significant milestone in the groundbreaking collaboration between
IQVIA and AP-HP. By ensuring world class research, patients will
have greater access to new innovative therapies and transformed
health outcomes in the future.”
In 2019 AP-HP carried out more than 4,000 research projects,
including 1,850 sponsored by industry and 1,240 sponsored by AP-HP.
The GHU AP-HP Nord is particularly distinguished within the
following fields: neuroscience, hematology, immunology, oncology,
dermatology, gastro-intestinal diseases, infectious diseases,
inflammatory and renal transplantation diseases, cardiovascular
diseases, imaging and emergency care. The alliance between AP-HP
and IQVIA will increase the visibility of Europe's largest
university hospitals at an international level, particularly among
biotech companies specializing in biotechnology across North
America and Asia. For more information visit
https://www.iqvia.com/solutions/research-and-development/clinical-trials.
About AP-HP
Europe's leading hospital and university center (CHU), the AP-HP
and its 39 hospitals are organized into six university hospital
groups (AP-HP. Centre - University of Paris; AP-HP. Sorbonne
University; AP-HP. Nord - University of Paris; AP-HP. University of
Paris Saclay; AP-HP. Henri Mondor and AP-HP University Hospitals.
University Hospitals Paris Seine-Saint-Denis) and is structured
around five Paris universities. Closely linked to major research
organizations, AP-HP has three world-class university hospital
institutes (ICM, ICAN, IMAGINE) and the largest French health data
warehouse (EDS). A major player in applied research and health
innovation, the AP-HP holds a portfolio of 650 active patents, its
clinician researchers sign nearly 9,000 scientific publications
each year and more than 4,000 research projects are currently under
development, all sponsors combined. In 2015, the AP-HP also created
the AP-HP Research Foundation to support biomedical and health
research conducted in all its hospitals. http://www.aphp.fr
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced
analytics, technology solutions and contract research services to
the life sciences industry. Formed through the merger of IMS Health
and Quintiles, IQVIA applies human data science — leveraging the
analytic rigor and clarity of data science to the ever-expanding
scope of human science — to enable companies to reimagine and
develop new approaches to clinical development and
commercialization, speed innovation and accelerate improvements in
healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers
unique and actionable insights at the intersection of large-scale
analytics, transformative technology and extensive domain
expertise, as well as execution capabilities. With approximately
65,000 employees, IQVIA conducts operations in more than 100
countries.
IQVIA is a global leader in protecting individual patient
privacy. The company uses a wide variety of privacy-enhancing
technologies and safeguards to protect individual privacy while
generating and analyzing information on a scale that helps
healthcare stakeholders identify disease patterns and correlate
with the precise treatment path and therapy needed for better
outcomes. IQVIA’s insights and execution capabilities help biotech,
medical device and pharmaceutical companies, medical researchers,
government agencies, payers and other healthcare stakeholders tap
into a deeper understanding of diseases, human behaviors and
scientific advances, in an effort to advance their path toward
cures. To learn more, visit www.iqvia.com.
Click here to subscribe to Mobile Alerts for IQVIA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200123005259/en/
Tor Constantino, IQVIA Media Relations
(tor.constantino@iqvia.com) +1.484.567.6732
Andrew Markwick, IQVIA Investor Relations
(andrew.markwick@iqvia.com) +1.973.257.7144
IQVIA (NYSE:IQV)
Historical Stock Chart
From Feb 2024 to Mar 2024
IQVIA (NYSE:IQV)
Historical Stock Chart
From Mar 2023 to Mar 2024